Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I

NCT00004333 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg per day prevents liver failure in at least 1 patient with tyrosinemia type I.

Conditions

  • Tyrosinemia, Type I

Interventions

DRUG

NTBC

Sponsors & Collaborators

Principal Investigators

  • Jess G. Thoene · University of Michigan

Study Design

Purpose
TREATMENT

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-11-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004333 on ClinicalTrials.gov